Less than a month after Phase III-stage anti-CD20 antibody ocrelizumab dropped out of the race to market in the already crowded rheumatoid arthritis space, Pfizer Inc. said it was dropping work on TRU-105, the lead molecule in its RA collaboration with Trubion Pharmaceuticals Inc., in favor of a next-generation program. (BioWorld Today) Read More
